Literature DB >> 6896818

Effects of molsidomine on the coronary circulation in anesthetized dogs.

V B Fiedler, R E Nitz.   

Abstract

The intravenous effects of molsidomine on the coronary circulation, myocardial oxygen consumption, and hemodynamics were investigated in anesthetized, open-chest dogs. Left coronary artery flow was reduced after drug administration, while coronary resistance remained unaffected. The coronary arteriovenous oxygen difference did not change after molsidomine. Myocardial oxygen consumption was significantly reduced. Stroke work of the heart was diminished. Molsidomine caused a dose-dependent decrease in aortic and left ventricular pressures (after-load) as well as a sustained fall in left ventricular end-diastolic and mean pulmonary artery pressures (preload). Heart rate and contractility were only moderately affected. Stroke volume and cardiac output decreased significantly for the experimentation time, while total peripheral resistance increased after 0.25 mg/kg molsidomine. All observed effects of the drug can be explained by extracardiac effects: an increase in venous capacity. No direct effects of molsidomine on myocardial function could be noted. The fall in blood pressure was not induced by vasodilatation of peripheral arteriolar vessels but occurred as sequel of the reduced cardiac output following decreased ventricular filling. Molsidomine improved the oxygen supply-demand balance by decreasing external work of the heart and hence myocardial oxygen demand.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6896818     DOI: 10.1007/bf01908042

Source DB:  PubMed          Journal:  Basic Res Cardiol        ISSN: 0300-8428            Impact factor:   17.165


  15 in total

1.  Effect of nitrates and other coronary dilators on large and small coronary vessels: an hypothesis for the mechanism of action of nitrates.

Authors:  M M Winbury; B B Howe; M A Hefner
Journal:  J Pharmacol Exp Ther       Date:  1969-07       Impact factor: 4.030

2.  Coronary collateral vasodilator action of N-ethoxycarbonyl-3-morpholinosydnonimine (SIN-10) in heart with chronic coronary insufficiency in dogs.

Authors:  M Hirata; K Kikuchi
Journal:  Jpn J Pharmacol       Date:  1970-06

Review 3.  Physiologic approach to the treatment of angina pectoris.

Authors:  D T Mason; J F Spann; R Zelis; E A Amsterdam
Journal:  N Engl J Med       Date:  1969-11-27       Impact factor: 91.245

4.  Haemodynamic effects of molsidomin.

Authors:  K R Karsch; K P Rentrop; H Blanke; H Kreuzer
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

5.  Hemodynamic and myocardial effects of long-lasting venodilation in the conscious dog: analysis of molsidomine in comparison with nitrates.

Authors:  J Holtz; E Bassenge; A Kolin
Journal:  Basic Res Cardiol       Date:  1978 Sep-Oct       Impact factor: 17.165

6.  Acute double blind trial of a new anti-anginal drug: molsidomine.

Authors:  S Guerchicoff; A Vazquez; H Kunik; S Drajer; F Díaz
Journal:  Eur J Clin Pharmacol       Date:  1978-06-19       Impact factor: 2.953

7.  Haemodynamic effects of molsidomine.

Authors:  V B Fiedler; J Scholtholt
Journal:  Arzneimittelforschung       Date:  1978

8.  [Effect of molsidomine on the regional distribution of cardiac output in the anaesthetized dog (author's transl)].

Authors:  J Scholtholt; V B Fiedler; M Keil
Journal:  Arzneimittelforschung       Date:  1978

9.  Long-lasting effect of oral molsydomine on exercise performance: a new antianginal agent.

Authors:  A Takeshita; M Nakamura; T Tajimi; H Matsuguchi; A Kuroiwa
Journal:  Circulation       Date:  1977-02       Impact factor: 29.690

10.  Effect of molsidomine on coronary collateral blood flow in acute myocardial ischemia.

Authors:  G J Gross; M Gharaibeh
Journal:  Eur J Pharmacol       Date:  1980-10-03       Impact factor: 4.432

View more
  1 in total

1.  Haemodynamic effects of oral molsidomine in pump failure complicating myocardial infarction.

Authors:  S Drajer; H Cercós; H Torres; A Vazquez; J L Cohn; N Romero; G Faerman; S Soifer; C M Nijensohn
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.